Targeting a common collaborator in cancer development.
Level V
Where this comes from
- Record sourced from PubMed, PMID 20826838.
- Also identified by DOI 10.1126/scitranslmed.3001251 and PMC identifier 3425950.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.
Medical subject headings
- Antibiotics, Antineoplastic
- Cell Line, Tumor
- Doxorubicin
- Indazoles
- Neoplasms
- Sulfonamides